Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-adMSCs for Trauma-Induced Acute Kidney Injury
NCT06654193Phase 2Recruiting
- Sponsor
- Hope Biosciences
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic HB-adMSCs in acute kidney injury (AKI), sponsored by Hope Biosciences. Primary endpoints: Incidence of infusion-related adverse events or serious adverse events at 1 year and Duration of Acute Kidney Injury at Stage 2 at 2 days. Started Feb 2026; status: recruiting.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06654193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654193.